Novartis stock holds steady as billion-dollar Alteogen deal and MS pill data reshape pipeline
Published on 09/03/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis (ISIN CH0012005267) stock was recently quoted at 131.40 CHF on the SIX Swiss Exchange as of September 3, 2026, leaving the share largely unchanged versus the prior close according to market data from finanzen.ch. This stable trading comes as investors weigh a licensing option with Alteogen worth up to USD 3.2 billion and fresh late-stage results for the multiple sclerosis pill remibrutinib reported in early September 2026.
Pipeline reshaped by Alteogen deal and remibrutinib data
A major catalyst for Novartis in September 2026 is a new option and license agreement with South Korean biotech company Alteogen covering its recombinant human hyaluronidase ALT-B4 for subcutaneous formulations. According to an article on DailyPharm summarizing a filing to Korean regulators dated September 3, 2026, the total deal value could reach up to USD 3.223 billion if all options are exercised and development and commercial milestones are achieved, highlighting Novartis's willingness to invest heavily in drug delivery technologies for biologics. The same coverage notes that the agreement grants Novartis exclusive rights linked to ALT-B4 for specific products, positioning the Swiss group to expand subcutaneous versions of its therapies in coming years.
Parallel to the Alteogen transaction, Novartis has reported strong late-stage results for its oral multiple sclerosis candidate remibrutinib. A report compiled by Zacks on September 2, 2026 indicates that remibrutinib met the main goal in two large phase III studies in multiple sclerosis, delivering positive efficacy outcomes versus control and underpinning Novartis's neurology pipeline. Ground News also highlights that Novartis stock rose after disclosure of the remibrutinib trial results, suggesting that the market sees potential for the pill to complement or partially replace existing MS treatments.
Cell therapy pause adds a safety counterweight
Balancing these positive developments, Novartis has simultaneously paused eight clinical trials of its experimental CAR-T cell therapy candidate known as rap-cel after serious immune reactions in some participants. As detailed in a September 3, 2026 healthcare article on Yahoo Finance, three patients died following severe immune effector cell-associated hemophagocytic syndrome, a rare but potentially life-threatening complication of CAR-T approaches. Novartis is reviewing the cases with regulators and independent safety boards, and the suspension currently affects rap-cel programs in autoimmune and neurological conditions such as lupus, rheumatoid arthritis, multiple sclerosis, vasculitis and myasthenia gravis, while cancer studies remain unaffected.
For investors, this combination of a high-value licensing option, encouraging late-stage oral MS data and a safety-driven pause in cell therapy trials underscores how Novartis is pursuing a diversified approach to immune and neurological diseases. The Alteogen agreement strengthens its ability to offer subcutaneous formulations that may improve patient convenience, remibrutinib adds a potential new oral option in MS, and the rap-cel pause illustrates the risk management required in advanced cell therapies. Together, these developments give a fuller picture of Novartis's pipeline evolution as of early September 2026.
Job cuts in Basel underline ongoing restructuring
Beyond pipeline news, Novartis is continuing to adjust its manufacturing and development footprint in Switzerland. According to coverage by the Economic Times' pharma section dated September 3, 2026 and reporting based on company statements, Novartis could cut about 130 jobs at a Basel site as part of a relocation that was first announced in 2022. Around 200 people are currently employed at the site in Kleinbasel, and the laboratories and support activities are due to be transferred to the main Basel campus by the end of 2028. A separate report from Swissinfo on September 2, 2026 confirms that support laboratories, analytical testing and technical development functions will be moved to Basel, illustrating that the restructuring plan has a multiyear timeline.
These measures reflect Novartis's broader strategy to streamline operations while concentrating key functions on central sites. For shareholders, the planned reduction of roughly 130 positions out of about 200 at the Kleinbasel site represents a significant local downsizing, but in the context of Novartis's global workforce it is a targeted measure rather than a wholesale retrenchment. The relocation could help reduce fixed costs and simplify internal processes, supporting margins over the medium term once the transition is completed by 2028.
Novartis stock trading steady in the SMI
The reaction of Novartis stock to this mix of news has so far been muted. Market data from finanzen.ch show that the share traded around 131.44 CHF at 09:28 on September 3, 2026 on the SIX Swiss Exchange, essentially flat compared with the previous day's level, and later quoted at 131.40 CHF at 12:28 the same day. This places Novartis among the neutral contributors in the Swiss Market Index (SMI), which was reported at roughly 14,354 points in the morning quote and 14,382.19 points by midday on September 3, 2026.
The relatively stable price near 131 CHF suggests that investors are balancing the upside potential from the Alteogen deal and remibrutinib trial success with the uncertainties around rap-cel safety and the operational changes in Basel. Importantly for DACH-focused readers, Novartis remains one of the heavyweight constituents of the SMI, and its steady behavior on September 3, 2026 helped the index maintain levels above 14,300 points despite sector-specific volatility in healthcare names elsewhere.
More background on Novartis shares
Read additional headlines and regulatory filings linked to Novartis stock to understand how pipeline decisions, licensing agreements and restructuring moves are reflected in market sentiment.
Key product focus: multiple sclerosis therapies
In the therapeutic area of multiple sclerosis, Novartis already markets established treatments and now aims to expand its offering with the oral BTK inhibitor remibrutinib. The late-stage trial results disclosed in early September 2026 suggest that remibrutinib successfully achieved its primary endpoints in two large studies, positioning the pill to compete in the dynamic MS market if approved. For patients, an effective oral therapy can be an attractive alternative to injectable or infusion-based treatments, and for Novartis, the product would add a new revenue stream in neurology once commercialized.
Even though detailed revenue or sales guidance figures for remibrutinib were not specified in the September 2026 reports, analysts following Novartis generally view successful phase III data as a critical de-risking event. The combination of remibrutinib and the subcutaneous delivery platform accessed through the Alteogen deal could give Novartis more flexibility in how it designs and positions future immune and neurological therapies, potentially supporting both volume and pricing power in these segments over the long term.
Stock price snapshot and investor takeaway
As of September 3, 2026, Novartis stock trades on the SIX Swiss Exchange at around 131.40 CHF, with intraday quotes between 131.30 CHF at the start of trading and 131.44 CHF reported later in the morning. This price level keeps the share comfortably within the typical daily range and contributes to a stable Swiss Market Index environment on the same date. While exact intraday volume and market capitalization figures were not detailed in the available sources, the unchanged price behavior indicates that the market has not yet assigned a dramatic valuation shift to the latest pipeline and restructuring news.
Novartis at a glance
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of September 3, 2026, 12:28): 131.40 CHF
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: SMI
